|
1
|
Henske EP, Jóźwiak S, Kingswood JC,
Sampson JR and Thiele EA: Thiele: Tuberous sclerosis complex. Nat
Rev Dis Primers. 2(16035)2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Northrup H, Aronow ME, Bebin EM, Bissler
J, Darling TN, de Vries PJ, Frost MD, Fuchs Z, Gosnell ES, Gupta N,
et al: Updated international tuberous sclerosis complex diagnostic
criteria and surveillance and management recommendations. Pediatr
Neurol. 123:50–66. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Inoki K, Li Y, Zhu T, Wu J and Guan KL:
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR
signalling. Nat Cell Biol. 4:648–657. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Gao X, Zhang Y, Arrazola P, Hino O,
Kobayashi T, Yeung RS, Ru B and Pan D: Tsc tumor suppressor
proteins antagonize amino-acid-TOR signaling. Nat Cell Biol.
4:699–704. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Kwiatkowski DJ, Zhang H, Bandura JL,
Heiberger KM, Glogauer M, el-Hashemite N and Onda H: A mouse model
ot TSC1 reveals sex-dependent lethality from liver hemangiomas, and
up-regulation of p70S6 kinase activity in Tsc1 null cells.
Hum Mol Genet. 11:525–534. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tee AR, Fingar DC, Manning BD, Kwiatkowski
DJ, Cantley LC and Blenis J: Tuberous sclerosis complex-1 and -2
gene products function together to inhibit mammalian target of
rapamycin (mTOR)-mediated downatream signaling. Proc Natl Acad Sci
USA. 99:13751–13756. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kenerson HL, Aicher LD, True LD and Yeung
RS: Activated mammalian target of rapamycin pathway in the
pathogenesis of tuberous sclerosis complex renal tumors. Cancer
Res. 62:5645–5650. 2002.PubMed/NCBI
|
|
8
|
El-Hashemite N, Zhang H, Henske EP and
Kwiatkowski DJ: Mutation in TSC2 and activation of mammalian
target of rapamycin signaling pathway in renal angiomyolipoma.
Lancet. 361:1348–1349. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bissler JJ, McCormack FX, Young LR, Elwing
JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J,
et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex
or lymphangioleiomyomatosis. N Engl J Med. 358:140–151.
2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Krueger DA, Care MM, Holland K, Agricola
K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T and Franz
DN: Everolimus for subependymal giant-cell astrocytomas in tuberous
sclerosis. N Engl J Med. 363:1801–1811. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Davies M, Saxena A and Kingswood JC:
Management of everolimus-associated adverse events in patients with
tuberous sclerosis complex: A practical guide. Orphanet J Rare Dis.
12(35)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Manning BD, Logsdon MN, Lipovsky AI,
Abbott D, Kwiatkowski DJ and Cantley LC: Feedback inhibition of Akt
signaling limits the growth of tumors lacking Tsc2. Genes Dev.
19:1773–1778. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wan X, Harkavy B, Shen N, Grohar P and
Helman LJ: Rapamycin induces feedback activation of Akt signaling
through an IGF-1R-dependent mechanism. Oncogene. 26:1932–1940.
2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Carracedo A, Baselga J and Pandolfi PP:
Deconstructing feedback-signaling networks to improve anticancer
therapy with mTORC1 inhibitors. Cell Cycle. 7:3805–3809.
2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mi R, Ma J, Zhang D, Li L and Zhang H:
Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in
treating a tuberous sclerosis complex cell model. J Genet Genomics.
36:355–361. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin
M, Manning BD and Hotamisligil GS: Loss of the tuberous sclerosis
complex tumor suppressors truggers the unfolded protein response to
regulate insulin signaling and apoptosis. Mol Cell. 29:541–551.
2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yu J, Parkhitko AA and Henske EP:
Mammalian target of rapamycin signaling and autophagy: Roles in
lymphangioleiomyomatosis therapy. Proc Am Thorac Soc. 7:48–53.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Parkhitko A, Myachina F, Morrison TA,
Hindi KM, Auricchio N, Karbowniczek M, Wu JJ, Finkel T, Kwiatkowski
DJ, Yu JJ and Henske EP: Tumorigenesis in tuberous sclerosis
complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
Proc Natl Acad Sci USA. 108:12455–12460. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pollizzi K, Malinowska-Kolodziej I, Stumm
M, Lane H and Kwiatkowski D: Equivalent benefit of mTORC1 blockade
and combined PI3K-mTOR blockade in a mouse model of tuberous
sclerosis. Mol Cancer. 8(38)2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Siroky BJ, Yin H, Babcock JT, Lu L,
Hellmann AR, Dixon BP, Quilliam LA and Bissler JJ: Human
TSC-associated renal angiomyolipoma cells are hypersensitive to ER
stress. Am J Physiol Renal Physiol. 303:F831–F844. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Armijo ME, Campos T, Fuentes-Villalobos F,
Palma ME, Pincheira R and Castro AF: Rheb signaling and
tumorigenesis: mTORC1 and new horizons. Int J Cancer.
138:1815–1823. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gau CL, Kato-Stankiewicz J, Jiang C,
Miyamoto S, Guo L and Tamanoi F: Farnesyltransferase inhibitors
reverse altered growth and distribution of actin filaments in
Tsc-deficient cells via inhibition of both rapamycin-sensitive and
-insensitive pathways. Mol Cancer Ther. 4:918–926. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Alves MM, Fuhler GM, Queiroz KC, Scholma
J, Goorden S, Anink J, Spek CA, Hoogeveen-Westerveld M, Bruno MJ,
Nellist M, et al: PAK2 is an effector of TSC1/2 signaling
independent of mTOR and a potential therapeutic target for tuberous
sclerosis complex. Sci Rep. 5(14534)2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sugiura H, Yasuda S, Katsurabayashi S,
Kawano H, Endo K, Takasaki K, Iwasaki K, Ichikawa M, Kobayashi T,
Hino O and Yamagata K: Rheb activation disrupts spine synapse
formation through accumulation of syntenin in tuberous sclerosis
complex. Nat Commun. 6(6842)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sugiura H, Shimada T, Moriya-Ito K, Goto
JI, Fujiwara H, Ishii R, Shitara H, Taya C, Fujii S, Kobayashi T,
et al: A farnesyltransferase inhibitor restores cognitive deficits
in Tsc2+/- mice through inhibition of Rheb1. J Neurosci.
23:2598–2612. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wu J, Liu T, Rios Z, Mei Q, Lin X and Cao
S: Heat shock proteins and cancer. Trends Pharmacol Sci.
38:226–256. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dimas DT, Perlepe CD, Sergentanis TN,
Misitzis I, Kontzoglou K, Patsouris E, Kouraklis G, Psaltopoulou T
and Nonni A: The prognostic significance of Hsp70/Hsp90 expression
in breast cancer: A systematic review. Anticancer Res.
38:1551–1562. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Inoue H, Uyama T, Suzuki T, Kazami M, Hino
O, Kobayashi T, Kobayashi K, Tadokoro T and Yamamoto Y:
Phosphorylated hamartin-Hsp70 complex regulates apoptosis via
mitochondrial localization. Biochem Biophys Res Commun.
391:1148–1153. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Woodford MR, Sager RA, Marris E, Dunn DM,
Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou
C, et al: Tumor suppressor Tsc1 is a new HSP90 co-chaperone that
facilitates folding of kinase and non-kinase clients. EMBO J.
36:3650–3665. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kobayashi T, Minowa O, Kuno J, Mitani H,
Hino O and Noda T: Renal carcinogenesis, hepatic hemangiomatosis,
and embryonic lethality caused by a germ-line Tsc2 mutation
in mice. Cancer Res. 59:1206–1211. 1999.PubMed/NCBI
|
|
31
|
Piao X, Kobayashi T, Wang L, Shiono M,
Takagi Y, Sun G, Abe M, Hagiwara Y, Zhang D, Okimoto K, et al:
Regulation of folliculin (the BHD gene product) phosphorylation by
Tsc2-mTOR pathway. Biochem Biophys Res Commun. 389:16–21.
2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Goncharova EA, Goncharov DA, Fehrenbach M,
Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A,
Albelda SM and Krymskaya VP: Prevention of alveolar destruction and
airspace enlargement in a mouse model of pulmonary
lymphangioleiomyomatosis (LAM). Sci Transl Med.
4(154ra134)2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Okura H, Kobayashi T, Koike M, Ohsawa M,
Zhang D, Arai H, Uchiyama Y and Hino O: Tuberin activates and
controls the distribution of Rac1 via association with p62 and
ubiquitin through the mTORC1 signaling pathway. Int J Oncol.
43:447–456. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sato T, Akasu H, Shimono W, Matsu C,
Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F and Hattori S: Rheb
protein binds CAD (Carbamoyl-phosphate synthetase 2, aspartate
transcarbamoylase, and dihydroorotase) protein in a GTP- and
effector domain-dependent manner and influences its cellular
localization and Carbamoyl-phosphate synthetase (CPSase) activity.
J Biol Chem. 290:1096–1105. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Liu HJ, Lizotte PH, Du H, Speranza MC, Lam
HC, Vaughan S, Alesi N, Wong KK, Freeman GJ, Sharpe AH and Henske
EP: TSC2-deficient tumors have evidence of T cell exhaustion and
respond anti-PD-1/anti-CTLA-4 immunotherapy. JCI Insight.
3(e98674)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang HX, Yang Y, Guo H, Hou DD, Zheng S,
Hong YX, Cai YF, Huo W, Qi RQ, Zhang L, et al: HSPB1 deficiency
sensitizes melanoma cells to hyperthermia induced cell death.
Oncotarget. 7:67449–67462. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Morgenstern JP and Land H: Advanced
mammalian gene transfer: High titre retroviral vectors with
multiple drug selection markers and a complementary helper-free
packaging cell line. Nucleic Acids Res. 18:3587–3596.
1990.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X,
Wang H, Cao L and Tang D: HSPB1 as a novel regulator of ferroptotic
cancer cell death. Oncogene. 34:5617–5625. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu CC, Li HH, Lin JH, Chiang MC, Hsu TW,
Li AF, Yen DH, Hsu HS and Hung SC: Esophageal cancer stem-like
cells resist ferroptosis-induced cell death by active Hsp27-GPX4
pathway. Biomolecules. 12(48)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Di Nardo A, Lenoël I, Winden KD, Rühmkorf
A, Modi ME, Barrett L, Ercan-Herbst E, Venugopal P, Behne R, Lopes
CAM, et al: Phenotypic screen with TSC-deficient neurons reveals
heat-shock machinery as a druggable pathway for mTORC1 and reduced
cilia. Cell Rep. 31(107780)2020.PubMed/NCBI View Article : Google Scholar
|
